Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Treasury Shares: 2020-2024

Historic Treasury Shares for Relay Therapeutics (RLAY) over the last 1 years, with Dec 2024 value amounting to $5.8 million.

  • Relay Therapeutics' Treasury Shares rose 94.12% to $5.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $5.8 million, marking a year-over-year increase of 94.12%. This contributed to the annual value of $5.8 million for FY2024, which is 94.12% up from last year.
  • According to the latest figures from Q4 2024, Relay Therapeutics' Treasury Shares is $5.8 million, which was up 94.12% from $3.0 million recorded in Q4 2023.
  • Relay Therapeutics' Treasury Shares' 5-year high stood at $5.8 million during Q4 2024, with a 5-year trough of $84,489 in Q4 2020.
  • Moreover, its 3-year median value for Treasury Shares was $3.0 million (2023), whereas its average is $3.5 million.
  • Data for Relay Therapeutics' Treasury Shares shows a peak YoY skyrocketed of 718.10% (in 2021) over the last 5 years.
  • Over the past 5 years, Relay Therapeutics' Treasury Shares (Quarterly) stood at $84,489 in 2020, then skyrocketed by 718.10% to $691,205 in 2021, then surged by 126.67% to $1.6 million in 2022, then soared by 90.98% to $3.0 million in 2023, then surged by 94.12% to $5.8 million in 2024.
  • Its Treasury Shares was $5.8 million in Q4 2024, compared to $3.0 million in Q4 2023 and $1.6 million in Q4 2022.